Taken together, the results indicate that HDAC4 can serve as a marker of CIN and, when combined with MGMT promoter methylation status, may be used to identify GBM patients who would benefit most from combined radiochemotherapy. Here, HDAC4 is linked to cervical squamous intraepithelial neoplasia.